Leiden, The Netherlands -- Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced that it intends to submit the Biologic License Application (BLA) to the US Food and Drug Administration (FDA) to obtain marketing approval for F

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that data from Phase 3 studies of Cinryze™ (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of MedicineThe paper entitled 'Nanofiltered C1 Inhibitor Concentrate for

read more>>

Clinical trials from two international research teams have shown that icatibant, a new drug that blocks the action of an inflammatory protein known as bradykinin, is safe and effective in treating acute attacks of hereditary angioedema, a potentially life-threatening conditionIn their report in th

read more>>

CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ:DYAX) today announced that it has launched its newly enhanced product website, featuring its comprehensive financial assistance programKALBITOR(R) (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years

read more>>

Leiden, The Netherlands -- Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Ruconest (Wit

read more>>

CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ: DYAX) and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical company Sigma-Tau SpA (Sigma-Tau), announced today a strategic partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE)

read more>>

EXTON, Pa. -- ViroPharma Incorporated (Nasdaq: VPHM) today provided an update on recent progress in Cinryze™ (C1 Esterase Inhibitor [Human]) manufacturing expansion activitiesViroPharma is increasing its Cinryze manufacturing capacity through two concurrent efforts. The first project, the p

read more>>

LEIDEN, The Netherlands and SEATTLE -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical and commercial supply of plasma-based fibrinogen and thrombin,

read more>>

LONDON -- The HAE Awareness Programme was launched today, an online interactive training programme aimed to increase awareness of Hereditary Angioedema (HAEDeveloped by an Editorial Board of HAE Experts and supported by an unrestricted educational grant from CSL Behring Ltd, http://www.hae-awarene

read more>>

OTTAWA, Canada -- CSL Behring Canada announced today that it has received Notice of Compliance for Berinert® (Human C1 Esterase InhibitorThe company may now market Berinert for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) of moderate and severe intensity. H

read more>>